In:
Human Psychopharmacology: Clinical and Experimental, Wiley, Vol. 29, No. 6 ( 2014-11), p. 568-577
Abstract:
Aprepitant is a neurokinin 1 receptor antagonist approved for prevention of chemotherapy‐induced and post‐operative nausea and vomiting. Early studies demonstrated promising antidepressant activity as monotherapy, although this was unsupported by subsequent phase 3 trials. This phase 2 study evaluated whether aprepitant potentiated the antidepressant effects of paroxetine. Methods Outpatients with major depressive disorder were randomized to aprepitant 200 mg + paroxetine 20 mg, paroxetine + placebo, or aprepitant + placebo for 6 weeks. The primary endpoint was change in HAMD‐17 total score. Secondary/exploratory endpoints included changes in HAMA, CGI‐S, CGI‐I, and HAMD Item‐1 scores at week 6. Results A total of 79, 78, and 79 patients received aprepitant + paroxetine, paroxetine + placebo, and aprepitant + placebo, respectively. At week 6, mean changes in HAMD‐17 were −11.0 (95% confidence interval [CI]: −12.7, −9.4), −11.7 (95% CI: −13.3, −10.0), and −9.5 (95% CI: −10.9, −8.1), respectively. Pairwise comparisons of HAMD‐17 change with combination therapy versus paroxetine alone demonstrated no significant difference ( p = 0.567). Changes in CGI‐S, CGI‐I, and HAMD Item‐1 scores were also comparable, although there was a greater reduction in anxiety (HAMA) with paroxetine alone than aprepitant + paroxetine ( p = 0.045). Adverse events were generally more common with the combination than either monotherapy. Conclusion Concomitant use of aprepitant + paroxetine for 6 weeks did not provide greater antidepressant benefit compared with paroxetine + placebo in patients with major depression. Copyright © 2014 John Wiley & Sons, Ltd.
Type of Medium:
Online Resource
ISSN:
0885-6222
,
1099-1077
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
2001446-6
SSG:
15,3
Permalink